- Home
- FLIC vs CRVS Comparison
FLIC vs CRVS Comparison
Compare FLIC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLIC
- CRVS
- Stock Information
- Founded
- FLIC 1927
- CRVS 2014
- Country
- FLIC United States
- CRVS United States
- Employees
- FLIC N/A
- CRVS N/A
- Industry
- FLIC Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- FLIC Finance
- CRVS Health Care
- Exchange
- FLIC Nasdaq
- CRVS Nasdaq
- Market Cap
- FLIC 273.2M
- CRVS 257.0M
- IPO Year
- FLIC N/A
- CRVS 2016
- Fundamental
- Price
- FLIC $11.12
- CRVS $2.99
- Analyst Decision
- FLIC Buy
- CRVS Strong Buy
- Analyst Count
- FLIC 1
- CRVS 5
- Target Price
- FLIC $16.56
- CRVS $12.63
- AVG Volume (30 Days)
- FLIC 83.5K
- CRVS 715.8K
- Earning Date
- FLIC 04-24-2025
- CRVS 05-05-2025
- Dividend Yield
- FLIC 7.40%
- CRVS N/A
- EPS Growth
- FLIC N/A
- CRVS N/A
- EPS
- FLIC 0.75
- CRVS N/A
- Revenue
- FLIC $84,928,000.00
- CRVS N/A
- Revenue This Year
- FLIC $18.14
- CRVS N/A
- Revenue Next Year
- FLIC N/A
- CRVS N/A
- P/E Ratio
- FLIC $15.24
- CRVS N/A
- Revenue Growth
- FLIC N/A
- CRVS N/A
- 52 Week Low
- FLIC $9.30
- CRVS $1.30
- 52 Week High
- FLIC $15.03
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- FLIC 30.67
- CRVS 26.38
- Support Level
- FLIC $12.10
- CRVS $3.06
- Resistance Level
- FLIC $12.60
- CRVS $3.31
- Average True Range (ATR)
- FLIC 0.34
- CRVS 0.36
- MACD
- FLIC -0.03
- CRVS -0.10
- Stochastic Oscillator
- FLIC -1.15
- CRVS 1.11
About FLIC First of Long Island Corporation (The)
First of Long Island Corp is a holding company that provides financial services. It offers services of saving accounts, current accounts, and capital gain accounts. The company also provides lending services, such as commercial and residential mortgage loans, industrial loans, small business credit scored loans, and other credit facilities. In addition, the company provides account reconciliation services, ATM Banking, bill payment, cash management services, mobile banking, online banking, and payroll services to privately owned businesses, professionals, consumers, and public bodies.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).